The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Monoclonal Antibodies Market Outlook 2024
Synopsis
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
The global Biosimilar Monoclonal Antibodies market was valued at US$ 3666 million in 2020 and is expected to reach US$ 27030 million by the end of 2027, growing at a CAGR of 33.2% during 2021-2027.
This report focuses on Biosimilar Monoclonal Antibodies volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Biosimilar Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Biosimilar Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
The global Biosimilar Monoclonal Antibodies market was valued at US$ 3666 million in 2020 and is expected to reach US$ 27030 million by the end of 2027, growing at a CAGR of 33.2% during 2021-2027.
This report focuses on Biosimilar Monoclonal Antibodies volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Biosimilar Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Biosimilar Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Index1 Biosimilar Monoclonal Antibodies Market Overview
1.1 Product Overview and Scope of Biosimilar Monoclonal Antibodies
1.2 Biosimilar Monoclonal Antibodies Segment by Type
1.2.1 Global Biosimilar Monoclonal Antibodies Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Biosimilar Monoclonal Antibodies Segment by Application
1.3.1 Global Biosimilar Monoclonal Antibodies Sales Comparison by Application: (2021-2027)
1.3.2 Oncology
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Global Biosimilar Monoclonal Antibodies Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Monoclonal Antibodies Revenue 2016-2027
1.4.2 Global Biosimilar Monoclonal Antibodies Sales 2016-2027
1.4.3 Biosimilar Monoclonal Antibodies Market Size by Region: 2016 Versus 2021 Versus 2027
2 Biosimilar Monoclonal Antibodies Market Competition by Manufacturers
2.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2016-2021)
2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biosimilar Monoclonal Antibodies Manufacturing Sites, Area Served, Product Type
2.5 Biosimilar Monoclonal Antibodies Market Competitive Situation and Trends
2.5.1 Biosimilar Monoclonal Antibodies Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biosimilar Monoclonal Antibodies Players Market Share by Revenue
2.5.3 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar Monoclonal Antibodies Retrospective Market Scenario by Region
3.1 Global Biosimilar Monoclonal Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Biosimilar Monoclonal Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.3.1 North America Biosimilar Monoclonal Antibodies Sales by Country
3.3.2 North America Biosimilar Monoclonal Antibodies Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.4.1 Europe Biosimilar Monoclonal Antibodies Sales by Country
3.4.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Region
3.5.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region
3.5.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.6.1 Latin America Biosimilar Monoclonal Antibodies Sales by Country
3.6.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.7.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country
3.7.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biosimilar Monoclonal Antibodies Historic Market Analysis by Type
4.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
4.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
4.3 Global Biosimilar Monoclonal Antibodies Price by Type (2016-2021)
5 Global Biosimilar Monoclonal Antibodies Historic Market Analysis by Application
5.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
5.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
5.3 Global Biosimilar Monoclonal Antibodies Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Celltrion
6.1.1 Celltrion Corporation Information
6.1.2 Celltrion Description and Business Overview
6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
6.1.5 Celltrion Recent Developments/Updates
6.2 Pfizer (Hospira)
6.2.1 Pfizer (Hospira) Corporation Information
6.2.2 Pfizer (Hospira) Description and Business Overview
6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
6.2.5 Pfizer (Hospira) Recent Developments/Updates
6.3 3SBIO
6.3.1 3SBIO Corporation Information
6.3.2 3SBIO Description and Business Overview
6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
6.3.5 3SBIO Recent Developments/Updates
6.4 Novartis (Sandoz)
6.4.1 Novartis (Sandoz) Corporation Information
6.4.2 Novartis (Sandoz) Description and Business Overview
6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
6.4.5 Novartis (Sandoz) Recent Developments/Updates
6.5 Dr Reddy’s
6.5.1 Dr Reddy’s Corporation Information
6.5.2 Dr Reddy’s Description and Business Overview
6.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
6.5.5 Dr Reddy’s Recent Developments/Updates
6.6 Celgen Biopharma
6.6.1 Celgen Biopharma Corporation Information
6.6.2 Celgen Biopharma Description and Business Overview
6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
6.6.5 Celgen Biopharma Recent Developments/Updates
6.7 Cadila Healthcare
6.6.1 Cadila Healthcare Corporation Information
6.6.2 Cadila Healthcare Description and Business Overview
6.6.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
6.7.5 Cadila Healthcare Recent Developments/Updates
6.8 Hisun Pharma
6.8.1 Hisun Pharma Corporation Information
6.8.2 Hisun Pharma Description and Business Overview
6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
6.8.5 Hisun Pharma Recent Developments/Updates
6.9 Torrent Pharmaceuticals
6.9.1 Torrent Pharmaceuticals Corporation Information
6.9.2 Torrent Pharmaceuticals Description and Business Overview
6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
6.9.5 Torrent Pharmaceuticals Recent Developments/Updates
7 Biosimilar Monoclonal Antibodies Manufacturing Cost Analysis
7.1 Biosimilar Monoclonal Antibodies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
7.4 Biosimilar Monoclonal Antibodies Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biosimilar Monoclonal Antibodies Distributors List
8.3 Biosimilar Monoclonal Antibodies Customers
9 Biosimilar Monoclonal Antibodies Market Dynamics
9.1 Biosimilar Monoclonal Antibodies Industry Trends
9.2 Biosimilar Monoclonal Antibodies Growth Drivers
9.3 Biosimilar Monoclonal Antibodies Market Challenges
9.4 Biosimilar Monoclonal Antibodies Market Restraints
10 Global Market Forecast
10.1 Biosimilar Monoclonal Antibodies Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biosimilar Monoclonal Antibodies by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Biosimilar Monoclonal Antibodies by Type (2022-2027)
10.2 Biosimilar Monoclonal Antibodies Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biosimilar Monoclonal Antibodies by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Biosimilar Monoclonal Antibodies by Application (2022-2027)
10.3 Biosimilar Monoclonal Antibodies Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biosimilar Monoclonal Antibodies by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Biosimilar Monoclonal Antibodies by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Biosimilar Monoclonal Antibodies Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Biosimilar Monoclonal Antibodies Covered in This Study
Table 5. Global Biosimilar Monoclonal Antibodies Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Biosimilar Monoclonal Antibodies Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Biosimilar Monoclonal Antibodies Manufacturing Sites and Area Served
Table 11. Manufacturers Biosimilar Monoclonal Antibodies Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Biosimilar Monoclonal Antibodies Sales by Region (2016-2021) & (K Units)
Table 16. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Table 17. Global Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 19. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 20. North America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 22. Europe Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 23. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 24. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Table 30. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 32. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 38. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2016-2021)
Table 39. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 40. Global Biosimilar Monoclonal Antibodies Revenue (Million US$) by Type (2016-2021)
Table 41. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2016-2021)
Table 42. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2016-2021)
Table 43. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2016-2021)
Table 44. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 45. Global Biosimilar Monoclonal Antibodies Revenue (Million US$) by Application (2016-2021)
Table 46. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2016-2021)
Table 47. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2016-2021)
Table 48. Celltrion Corporation Information
Table 49. Celltrion Description and Business Overview
Table 50. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Celltrion Biosimilar Monoclonal Antibodies Product
Table 52. Celltrion Recent Developments/Updates
Table 53. Pfizer (Hospira) Corporation Information
Table 54. Pfizer (Hospira) Description and Business Overview
Table 55. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product
Table 57. Pfizer (Hospira) Recent Developments/Updates
Table 58. 3SBIO Corporation Information
Table 59. 3SBIO Description and Business Overview
Table 60. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. 3SBIO Biosimilar Monoclonal Antibodies Product
Table 62. 3SBIO Recent Developments/Updates
Table 63. Novartis (Sandoz) Corporation Information
Table 64. Novartis (Sandoz) Description and Business Overview
Table 65. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product
Table 67. Novartis (Sandoz) Recent Developments/Updates
Table 68. Dr Reddy’s Corporation Information
Table 69. Dr Reddy’s Description and Business Overview
Table 70. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Dr Reddy’s Biosimilar Monoclonal Antibodies Product
Table 72. Dr Reddy’s Recent Developments/Updates
Table 73. Celgen Biopharma Corporation Information
Table 74. Celgen Biopharma Description and Business Overview
Table 75. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Celgen Biopharma Biosimilar Monoclonal Antibodies Product
Table 77. Celgen Biopharma Recent Developments/Updates
Table 78. Cadila Healthcare Corporation Information
Table 79. Cadila Healthcare Description and Business Overview
Table 80. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Cadila Healthcare Biosimilar Monoclonal Antibodies Product
Table 82. Cadila Healthcare Recent Developments/Updates
Table 83. Hisun Pharma Corporation Information
Table 84. Hisun Pharma Description and Business Overview
Table 85. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Hisun Pharma Biosimilar Monoclonal Antibodies Product
Table 87. Hisun Pharma Recent Developments/Updates
Table 88. Torrent Pharmaceuticals Corporation Information
Table 89. Torrent Pharmaceuticals Description and Business Overview
Table 90. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product
Table 92. Torrent Pharmaceuticals Recent Developments/Updates
Table 93. Production Base and Market Concentration Rate of Raw Material
Table 94. Key Suppliers of Raw Materials
Table 95. Biosimilar Monoclonal Antibodies Distributors List
Table 96. Biosimilar Monoclonal Antibodies Customers List
Table 97. Biosimilar Monoclonal Antibodies Market Trends
Table 98. Biosimilar Monoclonal Antibodies Growth Drivers
Table 99. Biosimilar Monoclonal Antibodies Market Challenges
Table 100. Biosimilar Monoclonal Antibodies Market Restraints
Table 101. Global Biosimilar Monoclonal Antibodies Sales Forecast by Type (2022-2027) & (K Units)
Table 102. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Type (2022-2027)
Table 103. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 104. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Type (2022-2027)
Table 105. Global Biosimilar Monoclonal Antibodies Sales Forecast by Application (2022-2027) & (K Units)
Table 106. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Application (2022-2027)
Table 107. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 108. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Application (2022-2027)
Table 109. Global Biosimilar Monoclonal Antibodies Sales Forecast by Region (2022-2027) & (K Units)
Table 110. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Region (2022-2027)
Table 111. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 112. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Region (2022-2027)
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilar Monoclonal Antibodies
Figure 2. Global Biosimilar Monoclonal Antibodies Market Share by Type in 2020 & 2027
Figure 3. Infliximab Product Picture
Figure 4. Rituximab Product Picture
Figure 5. Trastuzumab Product Picture
Figure 6. Adalimumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Biosimilar Monoclonal Antibodies Market Share by Application in 2020 & 2027
Figure 9. Oncology
Figure 10. Autoimmune Disease
Figure 11. Other
Figure 12. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Biosimilar Monoclonal Antibodies Market Size 2016-2027 (US$ Million)
Figure 14. Global Biosimilar Monoclonal Antibodies Sales 2016-2027 (K Units)
Figure 15. Global Biosimilar Monoclonal Antibodies Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. Biosimilar Monoclonal Antibodies Sales Share by Manufacturers in 2020
Figure 17. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Biosimilar Monoclonal Antibodies Players: Market Share by Revenue in 2020
Figure 19. Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Figure 21. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region in 2020
Figure 22. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Figure 23. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in 2020
Figure 24. U.S. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Biosimilar Monoclonal Antibodies by Type (2016-2021)
Figure 49. Sales Market Share of Biosimilar Monoclonal Antibodies by Application (2016-2021)
Figure 50. Sales Market Share of Biosimilar Monoclonal Antibodies by Application in 2020
Figure 51. Revenue Share of Biosimilar Monoclonal Antibodies by Application (2016-2021)
Figure 52. Revenue Share of Biosimilar Monoclonal Antibodies by Application in 2020
Figure 53. Manufacturing Cost Structure of Biosimilar Monoclonal Antibodies
Figure 54. Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
Figure 55. Biosimilar Monoclonal Antibodies Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
